Rituximab® and high dose methylprednisolone (HDMP) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.

被引：0
|
作者：
Castro, JE
Bole, J
Prada, CE
Kipps, TJ
机构：
[1] Univ Calif San Diego, John & Rebecca Moores Canc Ctr, La Jolla, CA 92093 USA
[2] Chron Lymphocyt Leukemia Res Consortium, CRC, San Diego, CA USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2518
引用
收藏
页码：690A / 690A
页数：1
相关论文
共 50 条
  • [1] Rituximab® and high dose methylprednisolone (HDMP) as a first line treatment for patients with chronic lymphocytic leukemia
    Castro, JE
    Bole, JE
    Prada, CE
    Loria, O
    Kipps, TJ
    [J]. BLOOD, 2005, 106 (11) : 833A - 833A
  • [2] DOSE DENSE HIGH DOSE METHYLPREDNISOLONE (HDMP) AND RITUXIMAB (RTX) ARE EFFECTIVE IN RELAPSED OR REFRACTORY HIGH RISK CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Pileckyte, R.
    Jurgutis, M.
    Valceckiene, V.
    Stoskus, M.
    Gineikiene, E.
    Sejoniene, J.
    Degulys, A.
    Jakubauskas, A.
    Griskevicius, L.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 325 - 325
  • [3] Ofatumumab in combination with high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia.
    Castro, Januario E.
    Choi, Michael Y.
    Carvajal, Tomas
    Li, Hongying
    James, Danelle Frances
    Messer, Karen
    Kipps, Thomas J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Combined Rituximab and high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia.
    Bole, J
    Yan, L
    Tsukada, N
    Kipps, TJ
    [J]. BLOOD, 2002, 100 (11) : 802A - 802A
  • [5] Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia
    J E Castro
    M Y Choi
    T Carvajal
    E Almahasnah
    J Chang
    D F James
    T J Kipps
    [J]. Blood Cancer Journal, 2014, 4 : e258 - e258
  • [6] Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia
    Castro, J. E.
    Choi, M. Y.
    Carvajal, T.
    Almahasnah, E.
    Chang, J.
    James, D. F.
    Kipps, T. J.
    [J]. BLOOD CANCER JOURNAL, 2014, 4 : e258 - e258
  • [7] Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia
    Pileckyte, Regina
    Jurgutis, Mindaugas
    Valceckiene, Vilma
    Stoskus, Mindaugas
    Gineikiene, Egle
    Sejoniene, Jurgita
    Degulys, Andrius
    Zvirblis, Tadas
    Griskevicius, Laimonas
    [J]. LEUKEMIA & LYMPHOMA, 2011, 52 (06) : 1055 - 1065
  • [8] High dose Rituximab in chronic lymphocytic leukemia.
    Jain, D
    Dutcher, JP
    Wiernik, PH
    [J]. BLOOD, 2003, 102 (11) : 359B - 360B
  • [9] Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia
    Pileckyte, Regina
    Valceckiene, Vilma
    Stoskus, Mindaugas
    Matuzeviciene, Reda
    Sejoniene, Jurgita
    Zvirblis, Tadas
    Griskevicius, Laimonas
    [J]. MEDICINA-LITHUANIA, 2019, 55 (11):
  • [10] Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia
    Smolej, Lukas
    Doubek, Michael
    Panovska, Anna
    Simkovic, Martin
    Brychtova, Yvona
    Belada, David
    Motyckova, Monika
    Mayer, Jiri
    [J]. LEUKEMIA RESEARCH, 2012, 36 (10) : 1278 - 1282
12345